Name | GLP-1(28-36)amide acetate |
Description | GLP-1(28-36)amide acetate inhibits mitochondrial permeability transition with antioxidant, anti-diabetic and cardioprotection activities. |
In vitro | The plasma half-life of GLP-1(28-36)amide acetate is longer in human hepatocytes (24 min) than that in mouse hepatocytes (13 min). GLP-1(28-36)amide acetate (100 nM) on hepatocytes modulates mitochondrial oxidative metabolism including gluconeogenesis in mitochondria of hepatocytes[1]. |
In vivo | In high-fat diet-fed mice, GLP-1(28-36)amide acetate (18.5 nmol/kg) improved hepatic glucose disposal. In diet-induced obese mice, GLP-1(28-36)amide acetate (18.5 nmol/kg BW/day) diminishes the development of hepatic steatosis. In male C57BL6/J mice, administration of GLP-1(28-36)amide acetate for 20 min to, then isolated hearts underwent 30 min of global ischemia and 40 min of reperfusion, the recovery of left ventricular developed pressure is significantly great. In a β-cell injury diabetic mouse model, GLP-1(28-36)amide acetate (18 nmol/kg; i.p.) shows cytoprotective effect on pancreatic β cells by promoting proliferation and increasing mass[1]. |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 11.48 mg/mL (10 mM)
|
Keywords | GLP 1(28 36)amide acetate | GLP1(2836)amide acetate | GLP-1amide acetate(1225021-13-5 Free base) | GLP-1amide Acetate |
Inhibitors Related | Thiamine monochloride | 2-Heptanol | Butylated hydroxytoluene | Propyl gallate | L-Tartaric acid | Neohesperidin | Sulbutiamine | m-Coumaric acid | L-Cystine | Chrysin |
Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Obesity Compound Library | Peptide Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |